PTGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PTGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Protagonist Therapeutics's enterprise value is $2,024.1 Mil. Protagonist Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $155.6 Mil. Therefore, Protagonist Therapeutics's EV-to-EBITDA for today is 13.01.
The historical rank and industry rank for Protagonist Therapeutics's EV-to-EBITDA or its related term are showing as below:
During the past 10 years, the highest EV-to-EBITDA of Protagonist Therapeutics was 15.09. The lowest was -25.19. And the median was -4.15.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-10-08), Protagonist Therapeutics's stock price is $43.96. Protagonist Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $2.620. Therefore, Protagonist Therapeutics's PE Ratio (TTM) for today is 16.78.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The historical data trend for Protagonist Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -1.01 | -9.46 | -10.69 | -2.38 | -10.88 |
Protagonist Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -8.88 | -4.29 | -10.88 | 9.04 | 9.53 |
For the Biotechnology subindustry, Protagonist Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Protagonist Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Protagonist Therapeutics's EV-to-EBITDA falls into.
Protagonist Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 2024.050 | / | 155.61 | |
= | 13.01 |
Protagonist Therapeutics's current Enterprise Value is $2,024.1 Mil.
Protagonist Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $155.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagonist Therapeutics (NAS:PTGX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Protagonist Therapeutics's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 43.96 | / | 2.620 | |
= | 16.78 |
Protagonist Therapeutics's share price for today is $43.96.
Protagonist Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.620.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Protagonist Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Asif Ali | officer: Chief Financial Officer | 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560 |
William D. Waddill | director | C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080 |
Patel Dinesh V Ph D | director, officer: President and CEO | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
Suneel Gupta | officer: Chief Development Officer | 7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560 |
Arturo Md Molina | officer: Chief Medical Officer | 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024 |
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Lewis T Williams | director | C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Sarah B. Noonberg | director | 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Sarah A O'dowd | director | 3185 LAURELVIEW COURT, FREMONT CA 94538 |
Harold E Selick | director | |
Bryan Giraudo | director | 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560 |
Donald A. Kalkofen | officer: Chief Financial Officer | 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560 |
David Y Liu | officer: Chief Scientific Officer | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
Chaitan Phd Khosla | director | 3832 BAY CENTER PLACE, HAYWARD CA 94545 |
Richard S Shame | officer: Chief Medical Officer | C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035 |
From GuruFocus
By ACCESSWIRE • 08-01-2024
By ACCESSWIRE • 02-22-2024
By GuruFocus Research • 03-02-2024
By GuruFocus Research • 04-03-2024
By ACCESSWIRE • 07-22-2024
By ACCESSWIRE • 02-12-2024
By ACCESSWIRE • 03-07-2024
By ACCESSWIRE • 02-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.